Tumor cell group via phospholipase A2 is involved in prostate cancer development

Prostate

Volumn 71, Issue 4, 2011, Pages 373-384

  Li, Hui ^a,c   Zhang, Hong ^a,b   Wei, Gang ^a,c   Cai, Qingchun ^a   Yan, Libo ^a   Xu, Yan ^a  

^a INDIANA UNIVERSITY   (United States)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c JILIN PROVINCIAL CANCER HOSPITAL   (China)

Author keywords

calcium independent phospholipase A2beta; group VIA phospholipase A2 (iPLA2 ); lysophosphatidic acid (LPA); lysophosphatidylcholine (LPC); prostate cancer (PCa)

Indexed keywords

LYSOPHOSPHATIDIC ACID; PHOSPHOLIPASE A2 GROUP VI;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; GROUP IV PHOSPHOLIPASES A2; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS;

EID: 79251518631     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21251     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
2. Balsinde J, Balboa MA,. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 2005; 17 (9): 1052-1062.
3. Balsinde J, Balboa MA, Insel PA, Dennis EA,. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 1999; 39: 175-189.
4. Burke JE, Dennis EA,. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009; 50 (Suppl): S237-S242.
5. Cummings BS,. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 2007; 74 (7): 949-959.
6. Wilkins WP III, Barbour SE,. Group VI phospholipases A2: Homeostatic phospholipases with significant potential as targets for novel therapeutics. Curr Drug Targets 2008; 9 (8): 683-697.
7. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P,. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 2006; 240 (1): 9-16.
8. Sun B, Zhang X, Talathi S, Cummings BS,. Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. J Pharmacol Exp Ther 2008; 326 (1): 59-68.
9. Nicotera TM, Schuster DP, Bourhim M, Chadha K, Klaich G, Corral DA,. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells. Prostate 2009; 69 (12): 1270-1280.
10. Aoki J, Inoue A, Okudaira S,. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008; 1781 (9): 513-518.
11. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, Jones SS,. A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J Biol Chem 1997; 272 (13): 8567-8575.
12. Raynal P, Montagner A, Dance M, Yart A,. Lysophospholipids and cancer: Current status and perspectives. Pathol Biol (Paris) 2005; 53 (1): 57-62.
13. Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, Kim KS, Cristina KL, Song L, Williams FS, Elson P, Markman M, Belinson J,. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3 (1): 23-32.
14. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR,. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002; 107: 259-283.
15. Mills GB, Moolenaar WH,. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3 (8): 582-591.
16. Murph M, Mills GB,. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007; 9 (28): 1-18.
17. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, Xu Y,. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 2007; 26 (20): 2894-2901.
18. Qi C, Park JH, Gibbs TC, Shirley DW, Bradshaw CD, Ella KM, Meier KE,. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol 1998; 174 (2): 261-272.
19. Daaka Y,. Mitogenic action of LPA in prostate. Biochim Biophys Acta 2002; 1582 (1-3): 265-269.
20. Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A, Daaka Y,. Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int J Cancer 2002; 102 (6): 572-579.
21. Xie Y, Gibbs TC, Mukhin YV, Meier KE,. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 2002; 277 (36): 32516-32526.
22. Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF,. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog 2006; 45 (7): 518-529.
23. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, Cui MZ,. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta 2007; 1771 (7): 883-892.
24. Bissell MJ, Weaver VM, Lelievre SA, Wang F, Petersen OW, Schmeichel KL,. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res 1999; 59 (7 Suppl): 1757s-1763s, discussion 1763s-1764s.
25. Bao S, Miller DJ, Ma Z, Wohltmann M, Eng G, Ramanadham S, Moley K, Turk J,. Male mice that do not express group VIA phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility. J Biol Chem 2004; 279 (37): 38194-38200.
26. Bao S, Bohrer A, Ramanadham S, Jin W, Zhang S, Turk J,. Effects of stable suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J Biol Chem 2006; 281 (1): 187-198.
27. Bao S, Song H, Wohltmann M, Ramanadham S, Jin W, Bohrer A, Turk J,. Insulin secretory responses and phospholipid composition of pancreatic islets from mice that do not express group VIA phospholipase A2 and effects of metabolic stress on glucose homeostasis. J Biol Chem 2006; 281 (30): 20958-20973.
28. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM,. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57 (16): 3325-3330.
29. Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL Jr, Schellhammer PF, Qian J, Ciavarra RP,. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy. Int J Cancer 2003; 107 (5): 773-780.
30. Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD,. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother 2004; 27 (1): 13-26.
31. Li H, Wang D, Zhang H, Kirmani K, Zhao Z, Steinmetz R, Xu Y,. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther 2009; 8 (6): 1692-1701.
32. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H,. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004; 279 (17): 17634-17639.
33. Ferté C, André F, Soria JC,. Molecular circuits of solid tumors: Prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010; 7: 367-380.
34. Morgan TM, Koreckij TD, Corey E,. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9 (2): 237-249.
35. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15 (15): 4799-4805.
36. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y,. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 2006; 66 (16): 7983-7990.
37. Sengupta S, Xiao YJ, Xu Y,. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 2003; 17 (11): 1570-1572.
38. Hasegawa Y, Murph M, Yu S, Tigyi G, Mills GB,. Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. Mol Oncol 2008; 2 (1): 54-69.
39. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, Wu XX,. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: Relevance to prostate cancer and benign hyperplasia. Prostate 2009; 69 (3): 283-292.
40. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, Sivashanmugam P, Moniri NH, Daaka Y,. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 2006; 147 (10): 4883-4892.
41. Song Y, Wilkins P, Hu W, Murthy KS, Chen J, Lee Z, Oyesanya R, Wu J, Barbour SE, Fang X,. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J 2007; 406 (3): 427-436.
42. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD, Xu Y,. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66 (6): 3006-3014.
43. Zhao X, Wang D, Zhao Z, Xiao Y, Sengupta S, Zhang R, Lauber K, Wesselborg S, Feng L, Rose TM, Shen Y, Zhang J, Prestwich G, Xu Y,. Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells. J Biol Chem 2006; 281 (39): 29357-29368.
44. Li H, Zhao Z, Wei G, Yan L, Wang D, Zhang H, Sandusky GE, Turk J, Xu Y,. Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development. FASEB J 2010; Jun 8. [Epub ahead of print] PMID: 20530749.
45. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S,. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008; 68 (3): 927-936.
46. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH,. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22 (14): 2790-2799.
47. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K,. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002; 277 (42): 39436-39442.
48. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H,. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158 (2): 227-233.
49. Nouh MA, Wu XX, Okazoe H, Tsunemori H, Haba R, Abou-Zeid AM, Saleem MD, Inui M, Sugimoto M, Aoki J, Kakehi Y,. Expression of autotaxin and acylglycerol kinase in prostate cancer: Association with cancer development and progression. Cancer Sci 2009; 100 (9): 1631-1638.
50. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH,. Lysophosphatidate-induced cell proliferation: Identification and dissection of signaling pathways mediated by G proteins. Cell 1989; 59 (1): 45-54.
51. Jenkins CM, Han X, Mancuso DJ, Gross RW,. Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPLA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. J Biol Chem 2002; 277 (36): 32807-32814.
52. McHowat J, Creer MH, Rickard A,. Stimulation of protease activated receptors on RT4 cells mediates arachidonic acid release via Ca2+ independent phospholipase A2. J Urol 2001; 165 (6 Pt 1): 2063-2067.
53. Vasta V, Meacci E, Catarzi S, Donati C, Farnararo M, Bruni P,. Sphingosine 1-phosphate induces arachidonic acid mobilization in A549 human lung adenocarcinoma cells. Biochim Biophys Acta 2000; 1483 (1): 154-160.